lestaurtinib: Clinical Trials

3 trials of lestaurtinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 unknown. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Unknown 1
Phase 22Completed 1, Unknown 1

Follow lestaurtinib: new trials by email Literature Review of lestaurtinib trials Research Report on lestaurtinib

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CEP-701 (Lestaurtinib) in Myelofibrosis
CEP-701 (Lestaurtinib) - Myelofibrosis, Essential Thrombocythemia
Phase 1 / Phase 2UnknownRonald Hoffman602008-04-012014-11-26
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
cytarabine, idarubicin, lestaurtinib - Leukemia
Phase 1 / Phase 2CompletedChildren's Oncology Group142007-06-012017-03-15
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
lestaurtinib - Neuroblastoma
Phase 1CompletedNew Approaches to Neuroblastoma Therapy Consortium472003-08-012023-04-10

Conditions studied

Congenital Abnormalities (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Neuroblastoma (1)  ·  Polycythemia Vera (1)  ·  Primary Myelofibrosis (1)  ·  Thrombocythemia, Essential (1)

Sponsors

Children's Oncology Group (1)  ·  New Approaches to Neuroblastoma Therapy Consortium (1)  ·  Ronald Hoffman (1)

Countries

United States (3)  ·  Canada (1)

Top investigators

Donald Small, MD, PhD (1)  ·  Garrett M. Brodeur, MD (1)  ·  John M. Maris, MD (1)  ·  Patrick A. Brown, MD (1)  ·  Ronald Hoffman, MD (1)

Results publications

PMID 25563429

NIH funding

P01CA081403 (1), P01CA108671 (1)